Issue 153 • April 2025

Are European biopharma manufacturers ‘nearshoring’?

Experts debate whether European manufacturers are preferring domestic operations as the continent competes with Asia and the US

Briefing

Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drug

Feature

Metabolism errors elicit therapy development challenges

Feature

GLP-1RAs and opioid use disorder: a new frontier in addiction treatment

Interview

USAID funding fallout: sponsors, and agencies may have to fill funding gap

Go to article: Home | Are European biopharma manufacturers ‘nearshoring’?Go to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: MilliporeSigmaGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Datwyler Company InsightGo to article: DatwylerGo to article: Frewitt Company InsightGo to article: In DepthGo to article: Are European biopharma manufacturers ‘nearshoring’?Go to article: Inborn errors of metabolism elicit unique challenges for therapy developmentGo to article: GLP-1RAs and opioid use disorder: a new frontier in addiction treatmentGo to article: European agencies catch up with speedier regulatory pathways for CGTs in the USGo to article: USAID funding fallout: sponsors, and agencies may have to fill funding gapGo to article: Pfizer’s bet on gene therapies in haemophilia has been a bustGo to article: SimtraGo to article: Zenatek Company InsightGo to article: ListingsGo to article: EventsGo to article: Excellence AwardsGo to article: Buyer's GuidesGo to article: Next issue